liver 2 Flashcards

1
Q

What is the definition of acute hepatitis?

A

Infection for less than 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the definition of chronic hepatitis?

A

Infection for more than 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the incubation period for Hepatitis A Virus (HAV)?

A

14–50 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some general symptoms of HAV infection?

A
  • Nausea
  • Vomiting
  • Diarrhea
  • Myalgia
  • Fever
  • Abdominal pain
  • Jaundice
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How is Hepatitis A primarily transmitted?

A

Through the fecal–oral route

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the mortality rate associated with HAV?

A

Less than 1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the main management approach for acute HAV infection?

A

Supportive care; avoid hepatotoxic medications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What antibody indicates recent HAV infection?

A

IgM antibody to HAV (anti-HAV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What populations require preexposure prophylaxis with HAV vaccine?

A
  • All children older than 1 year
  • People experiencing homelessness
  • International travelers
  • Men who have sex with men
  • Injection or non-injection drug users
  • People with occupational risk of exposure
  • Patients with chronic liver disease or HIV infection
  • Pregnant women at risk
  • Individuals with close contact with international adoptees
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the postexposure prophylaxis recommendation for unvaccinated individuals after HAV exposure?

A

Administer HAV vaccine or immune globulin within 2 weeks of exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the main mode of transmission for Hepatitis B Virus (HBV)?

A
  • Parenteral
  • Bodily fluids
  • Sexual contact
  • Perinatal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the risk of developing chronic HBV infection after an acute infection in adults?

A

2%–6%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the serologic markers for HBV infection?

A
  • HBsAg
  • HBcAg
  • HBeAg
  • Anti-HBs
  • Anti-HBc IgM
  • Anti-HBc IgG
  • Anti-HBe
  • HBV DNA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the first detectable serum antigen during acute HBV infection?

A

HBsAg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What does the presence of Anti-HBs indicate?

A

Protective immunity against HBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the treatment recommendations for patients with chronic HBV infection?

A
  • Monitor for spontaneous conversion
  • Consider antiviral treatment if ALT is elevated and HBV DNA is high
  • Treat patients meeting chronic infection criteria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Name two preferred antiviral medications for HBV treatment.

A
  • Tenofovir
  • Entecavir
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the significance of HBeAg-positive disease in HBV?

A

Indicates ongoing active viral replication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is a major side effect associated with reverse transcriptase inhibitors?

A

Lactic acidosis and severe hepatomegaly with steatosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the preferred antiviral therapies for HBV in patients with decompensated cirrhosis?

A
  • Tenofovir disoproxil fumarate
  • Tenofovir alafenamide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the dosing recommendation for Entecavir in treatment-naive patients?

A

0.5 mg orally once daily for patients older than 16 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the recommended monitoring for patients on Tenofovir?

A

Periodic monitoring of renal function and liver function tests

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the association of Tenofovir alafenamide in terms of renal and bone toxicity?

A

Associated with less renal and bone toxicity

This is significant in managing patients with chronic HBV infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are the best predictors of response to Pegylated interferon treatment?

A
  • High pretreatment ALT
  • Low serum HBV DNA
  • Presence of active inflammation on biopsy
  • Acquisition of infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What serious adverse effects are associated with interferon treatment?

A
  • Bone marrow suppression
  • Leukopenia
  • Thrombocytopenia
  • Depression
  • Pulmonary hypertension
26
Q

What is the recommended dosing for Pegasys (pegylated-α-2a)?

A

180 mcg subcutaneously once weekly for 48 weeks

27
Q

What are the treatment options for HBeAg positive HBV?

A
  • Entecavir
  • Tenofovir
28
Q

What are the adverse effects of oral agents for HBV?

A
  • Predisposition to infections
  • CNS effects (depression, psychosis, anxiety)
  • Flulike symptoms
  • Anorexia, alopecia, thyroid dysfunction
29
Q

What is the duration of treatment with PEG-IFNα for HBeAg negative HBV?

A

≥ 1 year

30
Q

What are the vaccination schedules for Hepatitis B vaccines for individuals aged 18 and older?

A
  • Heplisav-B: Two doses (0 and 1 month)
  • PreHevbrio: Three doses (0, 1, and 6 months)
  • Twinrix: Three doses (0, 1, and 6 months)
31
Q

What is the postexposure prophylaxis for children born to HBsAg-positive mothers?

A

First dose of vaccine plus HBV immune globulin within 12 hours of birth

32
Q

What are the main risk factors for Hepatitis C Virus (HCV) infection?

A
  • HIV infection
  • Current or former injection drug use
  • Maintenance hemodialysis
  • Prior transfusions or organ transplants
33
Q

What is defined as chronic Hepatitis C infection?

A

Presence of viral RNA in the serum for 6 months or more

34
Q

What are the clinical signs and symptoms of Hepatitis C infection?

A
  • Nausea
  • Abdominal pain
  • Jaundice
  • Fever
  • Malaise
35
Q

What is the significance of sustained virologic response (SVR) in Hepatitis C treatment?

A

SVR is the absence of detectable HCV RNA 12 weeks after treatment, considered a virologic cure

36
Q

What are the adverse effects associated with Ribavirin treatment?

A
  • Hemolytic anemia
  • Teratogenicity
  • Pancreatitis
  • Pulmonary dysfunction
37
Q

What is the weight-based dosing of Ribavirin for patients weighing 75 kg or less?

A

1000 mg daily

38
Q

What are the testing recommendations for HCV?

A
  • One-time testing for all individuals aged 18 and older
  • Pregnant women with each pregnancy
  • Individuals with HCV risk factors
39
Q

What is the primary method for initial screening of HCV?

A

Serum anti-HCV antibodies

40
Q

What is the recommended monitoring for patients receiving DAA therapy?

A

Monitor for HBV reactivation

41
Q

What is the recommended action if hemoglobin drops more than 2 g/dL during treatment?

A

Decrease the dose to 600 mg/day.

42
Q

What should be done if hemoglobin drops to less than 12 g/dL after dose reduction?

A

Discontinue treatment.

43
Q

What medications can be used to stimulate red blood cell production?

A

Epoetin or darbepoetin.

44
Q

Which HCV genotypes does sofosbuvir treat?

A

HCV genotypes 1–6.

45
Q

What is the dosing for sofosbuvir?

A

400 mg tablet once daily with or without food.

46
Q

What are the adverse effects of sofosbuvir?

A

Fatigue, headache.

47
Q

Which drug interactions should be avoided with sofosbuvir?

A
  • Potent P-glycoprotein inducers
  • Amiodarone
  • Acid-suppressive therapy
48
Q

What is the indication for the combination of velpatasvir and sofosbuvir?

A

Genotype 1–6 infection.

49
Q

What is the dosing for velpatasvir/sofosbuvir?

A

Velpatasvir 100 mg / sofosbuvir 400 mg fixed-dose combination tablet once daily for 12 weeks.

50
Q

What are the adverse effects of the combination velpatasvir/sofosbuvir?

A

Headache and fatigue.

51
Q

What is the indication for glecaprevir/pibrentasvir (Mavyret)?

A

Genotype 1–6 infection with or without compensated cirrhosis.

52
Q

What is the dosing for glecaprevir/pibrentasvir?

A

Three tablets once daily with food.

53
Q

What are the adverse effects associated with glecaprevir/pibrentasvir?

A

Headache, fatigue, nausea.

54
Q

What should be monitored when using Grazoprevir and Elbasvir?

A

ALT elevations and testing for NS5A resistance-associated substitutions.

55
Q

What is the indication for the combination of velpatasvir, sofosbuvir, and voxilaprevir?

A

Genotypes 1–6 infection in treatment-experienced patients.

56
Q

What are the adverse effects of velpatasvir, sofosbuvir, and voxilaprevir?

A

Headache, fatigue, diarrhea, nausea.

57
Q

What is the recommended treatment for treatment-naive patients without cirrhosis?

A

Glecaprevir/pibrentasvir daily with food for 8 weeks.

58
Q

What tests are performed at baseline for HCV monitoring?

A
  • HCV RNA
  • Genotype
  • Quantitative HCV RNA
  • CBC
  • Liver function tests
  • Calculated GFR
59
Q

What should be checked after HCV treatment to assess for SVR?

A

HCV RNA at 12 weeks.

60
Q

True or False: There is a vaccine available for HCV.

61
Q

What modifications can reduce the risk of HCV transmission?

A
  • Intravenous drug abuse prevention
  • Appropriate barrier contraception
  • Avoid blood exposure
62
Q

Fill in the blank: Sofosbuvir should not be coadministered with _______ due to symptomatic bradycardia.

A

Amiodarone